Overview

A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective disorder.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen, LP

Treatments:

Risperidone